Neuro-Oncology

Neuro-Oncology

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

10 Clinical Trials
Neuro-Oncology Phase II Accepting Patients
nct/study# NCT02523014 / A071401

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Learn More
Neuro-Oncology Phase II Accepting Patients
nct/study# NCT03149003 / BBI-DSP7888-201G

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Learn More
Neuro-Oncology Phase II Accepting Patients
nct/study# NCT04762069 / CNS-201

A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy

Learn More
Neuro-Oncology Phase I/II Accepting Patients
nct/study# NCT04421378 / XPORT-GBM-029

A Phase 1/2 Study of Selinexor in Combination with Standard of Care (SoC) Therapy for ACTIVEly Diagnosed or Recurrent Glioblastoma

Learn More
Neuro-Oncology Accepting Patients
nct/study# NCT04471844 / EF-32

EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of ACTIVEly Diagnosed Glioblastoma

Learn More
Neuro-Oncology Phase II/III Accepting Patients
nct/study# NCT04396860 / NRG-BN007

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With ACTIVEly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.